Targeted Medical Pharma Receives Notice of Issuance for Comprehensive Billing Patent

Before you go, we thought you'd like these...
Before you go close icon

Targeted Medical Pharma Receives Notice of Issuance for Comprehensive Billing Patent

LOS ANGELES--(BUSINESS WIRE)-- Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a biotechnology company that develops and distributes prescription medical foods to physicians and pharmacies, today announced it has received an Issue Notification from the United States Patent and Trademark Office (USPTO) regarding projected patent number 8370172, which relates to a system and method for submitting claims for a dispensed medication to a patient by point-of-care physicians. The USPTO indicated that it expects the patent will be issued on February 5th, 2013.


"The issuance of this patent further establishes our leadership position in the medical reimbursement arena at a time when electronic billing is growing among physicians in clinical practice," said William Shell, M.D., co-inventor of the patent, CEO and chief scientific officer at Targeted Medical Pharma, Inc. "This patent provides point of care physicians with a powerful tool to bill for medications utilized within their practices."

Visit http://bit.ly/TargetedMedicalPharmaUSPTOPatent or click here for more information regarding the patent.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company manufactures ten proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. and the Middle East through the company's subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. Targeted Medical Pharma also provides diagnostic testing as well as billing and collection services on behalf of dispensing physicians.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma's business strategy, outlook, objectives, plans, intentions or goals. The words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.



Media Contacts:
PondelWilkinson
George Medici | gmedici@pondel.com
Ron Neal | rneal@pondel.com
310-279-5980
or
Investor Contacts:
PondelWilkinson
Roger Pondel | Matt Sheldon
310-279-5975
investors@tmedpharma.com

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:

The article Targeted Medical Pharma Receives Notice of Issuance for Comprehensive Billing Patent originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners